Stay up-to-date on Halozyme Therapeutics, Inc. Common Stock (HALO) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com.
National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego,...
近日,HalozymeTherapeutics宣布将以每股11.00欧元的现金收购iPSC赛道企业Evotec,交易总价值预计超过20亿欧元(约153亿元),该价格较今年10月15日未受干扰的股价溢价109%。 Halozyme是一家拥有ENHANZE药物递送技术的创新企业,基于ENHANZE平台合作开发的皮下给药产品已有多款获批上市,包括利妥昔单抗、曲妥珠单抗和达雷妥尤单...
SAN DIEGO,Feb. 4, 2025/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results onTuesday, February 18, 2025, following the close of trading. Halozyme...
圣地亚哥 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) 今日宣布计划以每股11.00欧元的价格收购Evotec SE (NASDAQ: EVO),这笔全现金交易总价值20亿欧元。此次交易旨在打造一家全球领先的制药服务公司,显著扩大和多元化Halozyme的业务范围和财务前景。 这项拟议收购预计将利用Halozyme现有技术和Evotec的平台,创建一个...
重组人透明质酸酶( Halozyme Therapeutics, Inc.): 一种透明质酸调节剂药物,由Halozyme Therapeutics, Inc. (Halozyme Therapeutics, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: 透明质酸调节剂,治疗领域: 其他疾病,在研适应症: 药物辅助,在研
News See more Yahoo Finance • last month Update: Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version Yahoo Finance • 2 months ago Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now Yahoo Finance • 12 months ago ...
Halozyme Announces Roche Doses First Patient In Phase 3 Clinical Trial With Subcutaneous Herceptin(R)Halozyme Therapeutics, Inc
Halozyme Therapeutics Halozyme Therapeutics in Fortune Rankings 56100 Fastest-Growing Companies Updated:10/25/23 Country:U.S. Headquarters:San Diego Industry:Pharmaceuticals CEO:Helen Torley Website:https://halozyme.com Ticker:HALO Company type:Public...
Halozyme董事Jeffrey Henderson出售价值29.3万美元公司股票HALO 1.93% 根据公司公告,Halozyme Therapeutics, Inc. (NASDAQ:HALO)董事Jeffrey William Henderson于2025年3月3日出售了公司股票。这些交易是根据2024年9月17日制定的Rule 10b5-1预设交易计划执行的。据InvestingPro数据显示,HALO展现出强劲的财务健康状况,Piotr...